How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

CR

NASDAQ:CRBU
Get a brief AI stock analysisSaves ~ 15 minutes of your time

CR

Caribou Biosciences IncNASDAQ CRBU Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is CRBU undervalued compared to its fair value?

The fair value of CRBU stock is hidden USD. Relative to the market price of 2.4 USD Caribou Biosciences Inc is hidden.

Caribou Biosciences, Inc. is a clinical-stage genome-editing biopharmaceutical company. The Company is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients w...[More about valuation]

Caribou Biosciences Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

0.217 $B

Price:

2.4 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.462

FINANCIALS

Caribou Biosciences financial for reporting period

Income Statement

0.0024 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.046 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.041 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0024 B 100%
-0.046 B -1894%
-0.041 B -1698%

Balance Sheet

0.41 B
0.34 B

Financial Position Analysis

Assets

0.41 B
Current Assets
0.3 B
Total non-current assets
0.1 B

Total current liabilities
0.029 B
Total non-current liabilities
0.035 B

Cash Flow Statement

-0.039 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.037 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Caribou Biosciences fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-33 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-167 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-28 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Caribou Rating

Is CRBU attractive for investment based on fundamental analysis?

CRBU stock rating is hidden. Caribou Biosciences is a hidden by Eyestock methodology.

Get CRBU Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-345

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

10.854

Debt / Equity ratio:

ROE:

-33

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

CRBU analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for CRBU to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Caribou Biosciences Inc dividends

CRBU dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About CRBU stock

About the company Caribou Biosciences Inc

Market cap $B

0.217

Dividend yield

Shares outstanding

61.2997 B

Caribou Biosciences, Inc. is a clinical-stage genome-editing biopharmaceutical company. The Company is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. It is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.

CRBU profile

  • Ticker

    CRBU

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    23 July 2021

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    137

  • City

    Berkeley

  • Address

    2929 7Th Street, Ste 120

  • Cusip

    142038108

Frequently Asked Questions

What sector does Caribou operate in?

Caribou operates in Healthсare sector

What is market cap of Caribou?

Market cap of Caribou is 0.217 USD as of 24 Jul 2024

What is market price of one CRBU stock?

Market price of one CRBU stock is 2.4 USD as of 24 Jul 2024

What is Caribou revenue?

According to the recent report Caribou revenue is 2.429

What is Caribou net income?

According to the recent report Caribou net icnome is -41.234

What is Caribou net income growh rate?

Net income growth rate of Caribou is -1